Sensyne Health, a UK-based clinical artificial intelligence (AI) company, has entered a strategic research agreement with the Colorado Center for Personalized Medicine (CCPM) in the US.
The partners will use clinical AI research for better patient care and expediting medical research.
Sensyne noted that the move is part of its goal to create a health data platform with industrial scale and strong protection of patient data.
With a focus on large-scale personalised medicine, CCPM has a research biobank that delivers clinically actionable results. This combines personalised genomic information with clinical data.
The organisation’s health dataset comprises 7.3 million de-identified and anonymised patients and a biobank of more than 180,000 research participants. As part of the latest agreement, Sensyne will have ethical access to this data for medical research activities.
CCPM director Kathleen Barnes said: “Our partnership with Sensyne Health will lead to an optimisation of patient care, using personalised results to better inform research, clinical decision making, and potentially leading to new ways of diagnosing, preventing and treating illnesses.”
Sensyne Health has also agreed to a joint commercial clinical development alliance with Phesi and one of its pharmaceutical clients.
Under the alliance, Sensyne will analyse anonymised and de-identified real-world patient data with Phesi’s trial data to streamline a clinical trial programme for the client.
The companies will provide synthetic trial arms and clinical decision support tools integrating trial data and real-world patient data.
Phesi founder and president Dr Gen Li said: “Integrated predictive analytics is set to play a vital role in optimising clinical development, and our work together will enable more life sciences organisations to become data-driven.
“Unlocking the power of data through this approach is crucial to meeting unmet medical needs around the world.”
Sensyne and Phesi did not divulge the financial terms of their agreement.